Current Report Filing (8-k)
September 29 2016 - 4:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 28, 2016
Cynapsus
Therapeutics Inc.
(Exact name of registrant as specified in
its charter)
Canada
|
|
001-37426
|
|
98-1226819
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
828 Richmond Street West,
Toronto, Ontario, Canada
(Address of principal executive offices)
|
M6J 1C9
(Zip Code)
|
Registrant’s telephone number, including
area code:
416-703-2449
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation
FD Disclosure.
On September 28, 2016, Cynapsus Therapeutics
Inc. (the “Company”) issued a press release announcing that Institutional Shareholder Services (ISS) has recommended
that the Company’s shareholders and warrantholders vote FOR the special resolution to approve the previously announced plan
of arrangement with Sunovion CNS Development Canada ULC. The full text of the press release is being furnished as Exhibit 99.1
to this Form 8-K, and shall not be deemed filed under the United States Securities Exchange Act of 1934, as amended.
Item 9.01
Financial Statements and Exhibits.
d) Exhibits
The following exhibit is furnished herewith:
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release dated September 28, 2016.
|
SIGNATURES
Pursuant to the requirements of the United
States Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CYNAPSUS THERAPEUTICS INC.
|
|
|
|
Date: September 29, 2016
|
|
By:
/s/ Andrew Williams
|
|
|
Name: Andrew Williams
|
|
|
Title: Chief Operating Officer and Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release dated September 28, 2016.
|
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)
Historical Stock Chart
From Sep 2023 to Sep 2024